Skip to main content

CORRECTION article

Front. Oncol., 30 April 2020
Sec. Neuro-Oncology and Neurosurgical Oncology
This article is part of the Research Topic Molecular Advances in Diagnosis and Treatment of CNS Tumors View all 24 articles

Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells

\nPaul Dent
Paul Dent1*Laurence Booth
Laurence Booth1*Jane L. RobertsJane L. Roberts1Andrew PoklepovicAndrew Poklepovic2John F. HancockJohn F. Hancock3
  • 1Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, United States
  • 2Departments of Medicine, Virginia Commonwealth University, Richmond, VA, United States
  • 3Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, TX, United States

A Corrigendum on
Fingolimod Augments Monomethylfumarate Killing of GBM Cells

by Dent, P., Booth, L., Roberts, J. L., Poklepovic, A., and Hancock, J. F. (2020). Front. Oncol. 10:22. doi: 10.3389/fonc.2020.00022

In the original article, there was a mistake in Figure 7C as published. By error, the image for FAS-L treated with MMF was included twice; once correctly and once as FAS-L treated with vehicle control. The corrected Figure 7C for FAS-L assessments appears below.

FIGURE 7
www.frontiersin.org

Figure 7.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: fingolimod, dimethyl fumarate, Gilenya, Tecfidera, RAS, glioblastoma, microglia

Citation: Dent P, Booth L, Roberts JL, Poklepovic A and Hancock JF (2020) Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells. Front. Oncol. 10:684. doi: 10.3389/fonc.2020.00684

Received: 11 March 2020; Accepted: 14 April 2020;
Published: 30 April 2020.

Edited and reviewed by: Liam Chen, Johns Hopkins University, United States

Copyright © 2020 Dent, Booth, Roberts, Poklepovic and Hancock. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Paul Dent, cGF1bC5kZW50JiN4MDAwNDA7dmN1aGVhbHRoLm9yZw==; Laurence Booth, bGF1cmVuY2UuYm9vdGgmI3gwMDA0MDt2Y3VoZWFsdGgub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.